ProAlgaZyme is the company's only product. It is a liquid derived from algae grown in distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme.
The company announced it is in the process of creating a pharmaceutical division, to be operated through a subsidiary, in order to develop potential pharmaceutical applications for ProAlgaZyme and cholesterol reduction.
"We are forming this new division to focus on exploiting the potential pharmaceutical opportunities for ProAlgaZyme," said Thomas Ingolia, HEPI CEO.
HEP said trials resulted in a 32 percent reduction of cholesterol.
"The cholesterol reduction market has revenues of over $25b per year," said Ingolia. "The trial results also indicated that our product has the potential toreduce key markers of inflammation by 57 percent on average..."
Until now, HEP has been purely a nutraceutical company engaged in the development of this all-natural supplement product.